STAT

Five ideas that might steer Gawande as CEO of Amazon-backed health company

Atul Gawande has yet to speak out about his plans for leading the new Amazon-JPMorgan-Berkshire Hathaway health care organization, but his past speeches and writings provide some clues to what he might do in the job.

Here are five key points about Gawande’s views:

He has thoughts about how to reduce health care costs. Lots of thoughts.

The purported goal of is to decrease health care costs for employees of the three corporate giants, though when it was announced, JPMorgan CEO Jamie Dimon said it could “create solutions that benefit … potentially all Americans.” (It should be noted that Dimon later tried to reassure spooked health care companies that the company’s purpose was really only for the three founding firms, as the Wall.)

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks